NCT02334800View on ClinicalTrials.gov

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

October 9, 2016

Study Completion Date

October 9, 2016

Conditions

Healthy, Hepatic Insufficiency

Interventions

DRUG

Palbociclib 75 mg Capsule

Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

32825

Weston Diagnostics (Ultrasound Facility), Orlando